Stockscreener 앱 받기
38.60
2.63%
0.99
시간 외 거래:
38.12
-0.48
-1.24%
Neurogene Inc 주식(NGNE)의 최신 뉴스
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Certain Pre-Funded Warrants of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com
Balyasny Asset Management L.P. Expands Neurogene Inc (NGNE) Stak - GuruFocus
Neurogene (NGNE) Watch: Posts a 4.45% Loss to $37.67 in the Current Update; Trading Range: Support at $35.79 and Resistance at $39.55 Frame the Range on the DayMarket Leader Picks - vinanet.vn
Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateLong-Term Guidance - dars.gov.et
Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionGuidance Upgrade Report - vinanet.vn
Neurogene gearing up to apply for approval of Rett gene therapy - Rett Syndrome News
symbol__ Stock Quote Price and Forecast - CNN
NGNE Q1 2026 Earnings: Narrow EPS Miss Masks Positive Investor SentimentEarnings Forecast Report - vinanet.vn
Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusMoney Flow Index - vinanet.vn
Neurogene Inc. $NGNE Shares Bought by Renaissance Technologies LLC - MarketBeat
Neurogene Inc. (NGNE): Redmile Group and Jeremy Green disclose 9.9% stake - Stock Titan
Neurogene (NGNE) filers disclose 714,885-share Trails Edge stake at 4.5% - Stock Titan
Q3 Earnings Forecast for Neurogene Issued By HC Wainwright - marketbeat.com
Balyasny Asset Management (NGNE) discloses 5.18% Neurogene stake via Atlas fund - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166 - Moomoo
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Given New $166.00 Price Target at Canaccord Genuity Group - MarketBeat
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166 - TipRanks
Neurogene (NGNE) Dips 2% to $35.8: Gene Therapy Developer Holds Above Key SupportSector Neutral Pair - Vinanet
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com Nigeria
HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price - marketbeat.com
Canaccord lowers Neurogene stock price target on valuation review - Investing.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $63 - Moomoo
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Neurogene Inc. Stock 12‑Month Price Target Cut to $79.75, Implies 118% Upside - TradingView
Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Neurogene Inc. Stock 12‑Month Price Target Cut to $78.5, Implies 115% Upside - TradingView
NEUROGENE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $166 FROM $180 - Bitget
Neurogene Q2 Results: EPS widens to $(1.53), misses estimates - scanx.trade
Neurogene (NASDAQ:NGNE) Stock Price Down 7.8% on Disappointing Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029 - TipRanks
Form 8K Neurogene Inc For: 11 August By Investing.com - Investing.com Nigeria
Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndrome - Bitget
Neurogene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neurogene: Q2 Earnings Snapshot - AOL.com
Neurogene Reports Q2 Net Loss of $34.5 Million - Quiver Quantitative
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - marketscreener.com
NGNE Q1 2026 Earnings: Wider-than-Expected Loss Highlights R&D Investment, Shares Gain 2.41%ROIC Trend Report - vinanet.vn
Neurogene Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Buy" from Analysts - MarketBeat
Neurogene (NASDAQ:NGNE): What Should Readers Watch Around Friday’s New Company Catalyst? - Kalkine Media
NGNE|Neurogene Inc|Price:34.380|Chg%:+1.510 - TradingKey
Neurogene (NGNE) Pulls Back 2.1% to $32.89 as Gene Therapy Stock Holds Above Critical SupportETH Profile - vinanet.vn
NGNE Q1 2026 Earnings: Wider-than-Expected Loss Dents SharesEstimate Revision Count - vinanet.vn
Neurogene Inc. Revenue Breakdown – NASDAQ:NGNE - TradingView
Neurogene Inc (NGNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurogene Inc (NGNE) Institutional Confidence - TradingKey
NGNE|Neurogene Inc|Price:34.610|Chg%:-0.290 - TradingKey
Neurogene Inc (NGNE) Cash Flow - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):